Summary Report of Consolidated Financial Results
For the Nine Months Period ended December 31, 2016
February 9, 2017stCompany name: NIPRO CORPORATION
TSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Yoshihiko Sano, President and Representative Director
Contact person: Takehito Yogo, Director and General Manager of Corporate Planning Headquarters
TEL: (06)6372-2331
Filing date of quarterly reporting: February 14, 2017
Payment date of cash dividends: Supplemental material on quarterly reporting: No
Presentation on quarterly results: No(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Nine Months ended December 31, 2016 (From April 1, 2016 to December 31, 2016)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
9 months ended December 31, 2016
270,187(1.4)
26,14841.9
23,70070.7
14,071
0.7
9 months ended December 31, 2015
274,061
14.1
18,431
34.3
13,884(24.9)
13,968(3.8)
Note: Comprehensive income 9 months ended December 31, 2016: (3,833) million yen (- %)((70.1)%)

9 months ended December 31, 2016
9 months ended December 31, 2015

Earnings per share
Yen
83.52
82.35

(2) Consolidated Financial Position
Total Assets
Millions of yen
9 months ended December 31, 2016
723,904
Year ended March 31, 2016
708,882
Note: Equity

2.

9 months ended December 31, 2015: 5,696 million yen

Diluted Earnings per share
Yen
75.82
-

Net Assets
Millions of yen
163,855
175,507

9 months ended December 31, 2016: 154,049 million yen

Equity Ratio
%
21.3
23.4

Year ended March 31, 2016: 165,997 million yen

Dividends

Year ended March 31, 2016
Year ending March 31, 2017
Year ending March 31, 2017
(Forecast)

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
17.00
16.50
7.50
-

First-quarter
Yen-

Annual Dividends

Yen
33.50

17.00

24.50

Note: Revisions to the forecast of cash dividends in the current quarter: No
3.

Forecast of Consolidated Financial Results for the Year ending March 31, 2017 (From April 1, 2016 to March 31, 2017)(Note: The % displays in the line of year ending March 31, 2017 show increase/decrease ratio against the year ended March 31, 2016)

Operating
IncomeNet Sales
Millions of yen%

Millions of yen

Ordinary Income%

Millions of yen%

363,000(1.0)
29,00019.8
20,00036.8
Note: Revisions to the forecast of consolidated financial results in the current quarter: No
Year ending March 31, 2017

Net Income
Millions of yen

12,500%(36.6)

Earnings
per Share
Yen
74.44

*Notes(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0Removal: 0(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No[3] Change in accounting estimate: No[4] Restatement: No

Note: More information can be found in P.5 “2. Summary (Other) Information, (3) Changes in Accounting Policies andAccounting Estimate and Restatement” in the attachment.

(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
9 months ended December 31, 2016: 171,459,479 sharesYear ended March 31, 2016: 171,459,479 shares[2] Number of treasury stock at end of the period:
9 months ended December 31, 2016: 5,342,911 sharesYear ended March 31, 2016: 1,666,187 shares[3] Average number of shares during the period:
9 months ended December 31, 2016: 168,483,700 shares

9 months ended December 31, 2015: 169,629,310 shares

Note: Number of the treasury stocks as of December 31, 2016 included 503,100 shares, and as of March 31, 2016
included 716,300 shares owned by Trust and Custody Service Bank, Ltd (Trust Account E).

*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.
*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.4“1. Qualitative Information for the Nine-Month Period Ended December 31, 2016, (3) Commentary on
Forward-Looking Statements Including Forecast of Consolidated Financial Results” in the attachment.

Table of Contents

1.

2.

3.

Qualitative Information for the Nine-Month Period ended December 31, 20162(1) Commentary on Business Results

2(2) Analysis Concerning Financial Position

4(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results

4

Summary (Other) Information

5(1) Changes in Significant Consolidated Subsidiaries

5(2) Accounting Treatments Simplified or Unique for Preparation

5(3) Changes in Accounting Policies and Accounting Estimate and Restatement

5(4) Additional Information

5

Consolidated Financial Statements

5(1) Quarterly Consolidated Balance Sheets

5(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income

8(3) Notes Regarding Consolidated Financial Statement

10(Notes regarding going concern)

10(Notes regarding significant changes in the amount of shareholders’ equity)

10(Segment Information)

10

-1-

1. Qualitative Information for the Nine-Month Period Ended December 31, 2016
(1) Commentary on Business Results

For the third quarter of the consolidated cumulative period, in terms of the global economy, gradual economic recovery
in United States and Europe continues, while China also shows signs of improvement. As for the Japanese economy, theresults of the US Presidential election underpinned depreciation of the yen, and corporate earnings and personal
consumption also remained steady. However, due to a sense of unease toward the new US administration and the trend
toward anti-globalization which has manifested as Brexit, there is a growing sense of uncertainty about the future.
As a result, sales for the third quarter of the consolidated cumulative period were JPY 270,187 million. Sales for thesame period of the previous year included JPY 11,403 million in sales from the subsidiary company Nipro Diagnostics Inc,
which was sold at the end of the previous quarter, and due to the appreciation of the yen that continued during the current
period, year-to-year, there was a 1.4% reduction. In the context of profitability, operating income increased year-to-yearby 41.9% to JPY 26,148 million due to lowered cost of sales and other factors, and ordinary income increased
year-to-year by 70.7% to JPY 23.7 billion. Additionally, the third quarter net income attributed to the shareholders of theparent company is JPY 14,071 million. Extraordinary loss decreased by JPY 1,882 million compared to the same periodof the previous year. On the other hand, in a year-to-year comparison, because of the application of tax effect accounting
on the estimated gain on the sale of Nipro Diagnostics Inc., corporate tax adjustments decreased by JPY 6,624 million(reduction in tax burden rate), which is an increase of 0.7% from the same period of the previous year.
The overview of the results for the current quarter period under review by business segment is as follows.

(i)

Medical-Related Business
Domestic sales of Medical-Related Business saw a tougher market situation due to the revisions to medical service

fees and drug prices in April 2016. Under such circumstances, the sales of the Medical Sales Division remained solid ineach field such as injection-transfusion products, enteral-alimentation products, testing products, dialysis products,
cardiovascular products and cardiac surgery (CVS) products. Sales largely increased in multiple fields; especially HDF
filter and dialysis monitoring devices in the field of dialysis products, “HeartMateⅡ○
R ,” or Left Ventricular Assist Device, inthe field of cardiac surgery (CVS) products, and then “SeQuent○
R Please,” or Drug Eluting Balloon Catheter, in the field ofcardiovascular products. As for the Pharmaceutical Sales Division, the sales were steady due to the sales growth of theexisting products and the expansion of the market with the promotion policy of generic drugs and the launch of addenda
listing items in June and December 2016. However, the competitive environment of domestic market became fiercer by
the appearance of manufactures of original drugs running sideline business. In addition, large markets of new big listing
items have being continuously entered by over dozens of competitors and initial sales of AG (authorized generic) allows
to market occupation, that made the market price competition more intensified to impact significantly to sales and profit.
Therefore, we will further strengthen the sales promotion to dispensing pharmacies, diagnosis procedure combination(DPC) hospitals and prescribers. As well, we are trying to increase the share of drugs for oral and external use andworked harder for information offering activities of injectable drugs based on the collaboration with pharmaceuticalwholesalers.
Meanwhile, overseas sales, despite an increase in sales quantity of mainstay dialysis products such as dialyzers andhospital products, decreased from the same period of the previous year due to appreciation of the yen which lowered unit
prices of the products and also due to the sale of Nipro Diagnostics, Inc., a consolidated subsidiary. However, earnings
before income taxes increased thanks to foreign exchange gains related to revaluation of assets denominated in foreign
currencies at the end of the current quarter. We will promote direct sales activities by actively strengthening overseas
sales networks in order to quickly respond to front-line needs and expand sales. In India, a country which we place aparticular focus on, we established offices for our Indian sales subsidiary in three states (Assam, Bihar and Odisha)-2-during the current quarter period under review, totaling 16 offices. Through these sales offices, we have enhanced ourpresence in the market by providing more locally-oriented and finely-tuned services and responding to front-line needs.
New overseas manufacturing facilities (India, Indonesia, Bangladesh and Hefei in China) further improved theirproduction system and realized stable production expansion under established quality system to promote their sales
widely in their countries and surrounding areas.
As a result, net sales of this business decreased by 3.5% from the same period of the previous year to 195,656 million
yen.

(ii)

Pharmaceutical-Related BusinessIn the Pharmaceutical-Related Business, we have broadened our contracted manufacturing operation to encompass
contracts to develop products from the formulation design of drugs and to develop products using our expertisedeveloping and supplying vials, syringes, bags, and other packaging containers. We also endeavored to expand thecontracted business by offering a diverse range of detailed yet wide-ranging contract services, such as support forlifecycle management where we believe we can enhance the value-added features and realize distinct service
differentiation. Furthermore, efforts to upgrade and expand our contracted manufacturing capabilities for the dedicatedbiopharmaceuticals line and the lines at the high potency active pharmaceutical ingredients manufacturing plant
contributed to strong sales.
Sales of pharmaceutical containers and the devices for pharmaceutical preparation or administration steadily increased
by offering containers and systems suitable to each pharmaceutical product which we developed by ourselves or throughjoint development with pharmaceutical manufactures. Such efforts were made to meet various needs in the medical front,
including small-volume bags, materials for pre-filled syringes (plastic and glass), etc., on top of rubber stoppers forpharmaceutical and vaccine use and containers for kit products. In addition, under the government’s policy to curb medical
expenses, we have worked together with domestic and foreign pharmaceutical manufactures in enhancing
comprehensive lifecycle management of pharmaceutical products, taking into consideration the development of
combination products (our original collaboration between pharmaceutical products and medical devices), self-injection
systems, and dosage form/administrating path modification in the future.
As a result, net sales of this business increased 14.3% from the same period of the previous year to 52,902 million yen.

(iii) PharmaPackaging BusinessIn the PharmaPackaging Business, adding to the business of our conventional products, we have made efforts toengage in marketing through academic channels, by attending academic conferences for example, to understand theneeds of globalizing customers and acquire new demand. We have also promoted the development of new technologies
and new products domestically and overseas to support injectable formulations and filling processes, which require
quality with high stability.
For domestic department, under the policies of “One Nipro” and “One Stop Solution,” we changed the trade flow topharmaceutical companies in Japan starting this fiscal year and have started to sell pharmaceutical packaging materials
through the Pharmaceutical Business Division, aiming to achieve synergy with the Pharmaceutical-Related Business inthe areas of customer service, marketing, and product development. While sales for the current quarter increased, led bystrong sales of vials and thermos bottles, sales were affected by an increase in the elimination of internal sales between
segments caused by the change of trade flow. On the manufacturing end, despite the decline in production at the Biwako
Factory and the cost increase due to inventory adjustments at pharmaceutical companies of some products, we are
striving to thoroughly improve quality and the manufacturing process through the introduction of new equipment, among
other methods.

-3-

As for overseas sales, the continuing appreciation of yen during the current period and the uncertainty around the futureof the US and European market due to Brexit and the US presidential election, as well as the Chinese government’s push
to strengthen GMP which has led to the decrease of pharmaceutical companies has created a difficult market
environment. Regardless, we have succeeded in aggressively expanding sales of high-value-added products. The
resulting net sales amounted to almost the same level as the previous year, excluding the negative impact of foreign
currency conversion due to the appreciation of the yen. In manufacturing, in addition to the surge in shipments ofhigh-value-added products such as sterile syringes and VIALEX®, we pushed forward with automating manufacturing
processes at each factory, stabilization and improvement of quality through improved productivity efficiency, and cost
reduction. As a result, the rate of return has increased.
As a comprehensive manufacturer of pharmaceutical packaging materials, the PharmaPackaging Business Division willcontinue to strive to expand business by developing and introducing to the market advanced products that meet the
medical needs of countries all over the world.
As a result, net sales of this business decreased 13.3% from the same period of the previous year to 21,605 million yen.

(iv) Other BusinessAmong other business, sales from the real-estate rental business were 22 million yen (down by 7.2% from the same
period of the previous year).

(2) Analysis Concerning Financial Position
Analysis Concerning the Conditions of Assets, Liabilities and Net Assets
Total assets increased by 15,022 million yen from the end of the previous year to 723,904 million yen. Current assets
increased by 12,773 million yen primarily due to an increase of 6,634 million yen in notes and accounts receivable - trade,and noncurrent assets increased by 2,248 million yen primarily due to an increase of 6,202 million yen in investment
securities.
Total liabilities increased by 26,673 million yen from the end of the previous year to 560,049 million yen. Current
liabilities increased by 3,835 million yen primarily due to an increase of 7,406 million yen in short-term loans payable, andnoncurrent liabilities increased by 22,838 million yen primarily due to an increase of 23,093 million yen in long-term loans
payable.
Total net assets decreased by 11,651 million yen from the end of the previous year to 163,855 million yen.
Shareholders’ equity increased by 5,206 million yen and accumulated other comprehensive income decreased by 17,154
million yen. As a result, capital adequacy ratio decreased by 2.1% from the end of the previous year to 21.3%.

(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results
The future is becoming more and more uncertain due to the unease regarding the new US administration and thegrowing trend for countries around the world to look inward and prioritize domestic affairs. Even in this current environment,
our group continues to work toward achieving a consolidated sales goal of JPY 500 billion by FY 2020. We will focus on
accelerating the development of new technologies and new products, and making social contributions throughtechnological innovation, which in turn leads to business development, and will continue to further the concept of local
production and consumption.
At this moment, we have not made any revision to the forecast of consolidated financial results for the year ending March
31, 2017, which was announced on November 8, 2016.

-4-

2. Summary (Other) Information(1) Changes in Significant Consolidated Subsidiaries
N/A(2) Accounting Treatments Simplified or Unique for Preparation
N/A(3) Changes in Accounting Policies and Accounting Estimate and Restatement(Change in Accounting Policies)
Application of the Practical Solution on a change in depreciation method due to Tax Reform 2016
Following the Revisions of the Corporate Tax Law, the Company adopted "Practical Solution on a change indepreciation method due to Tax Reform 2016” (ASBJ PITF No.32, June 17, 2016) from the three-month period ended
June 30, 2016 and has applied the straight line method in place of declining balance method to the facilities andstructures of buildings acquired on or after April 1, 2016.
As a result, consolidated operating income, consolidated ordinary profit and surplus before income taxes in the ninemonths ended December 31, 2016 increased by 227 million yen respectively in comparison with the previous method.

(4) Additional Information
Application of Revised Implementation Guidance on Recoverability of Deferred Tax Assets
The Company has applied Revised Implementation Guidance on Recoverability of Deferred Tax Assets (ASBJ
Guidance No.26, March 28, 2016) from the three-month period ended June 30, 2016.

-5-5. Consolidated Financial Statements(1) [ Consolidated Balance Sheets](Millions of yen)
As ofMarch 31, 2016
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Net defined benefit asset
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-6-

As of
December 31, 2016

126,667
113,235
68,683
10,16723,851
6,380
20,115(983)
368,117

124,367
119,870
72,27812,255
24,817
5,863
22,370(931)
380,891

184,037(84,826)
99,211
217,074(154,911)
62,162
21,123
3,229(2,208)
1,021
27,643
46,976(34,382)
12,594
223,756

192,986(88,141)
104,844
221,371(158,177)
63,193
21,101
3,689(2,468)1,220
24,89847,817(35,809)
12,008227,266

28,8762,469
13,56644,91326,003
2,283
11,95040,23758,560253
3,947
15,625(6,292)
72,094
340,764
708,882

64,763268
2,340
13,735(5,598)75,509343,013723,904

(Millions of yen)
As ofMarch 31, 2016
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription rights to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Net defined benefit liability
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

-7-

As of
December 31, 2016

56,185
125,848
10,0002,262
1,044
12,004
389
4,266
3,733
79
12,753
23,579252,147

57,866133,255
10,000880
1,147
11,772
－
5,388
3,814
309
14,910
16,637
255,983

18,33025,00017,90025,000224,945
3,132
1,985
5,017
553
18
2,245
281,227
533,375

248,039
2,943
1,846
5,128
543
16
2,649
304,066
560,049

84,397－73,067(1,475)
155,990

84,397
1
83,079(6,282)
161,197(3,347)(12)
14,187(821)
10,007
9,509
175,507
708,882

(612)
(232)
(5,593)(709)(7,147)
9,806
163,855
723,904

(2) [Consolidated Statements of Income and Consolidated Statement of Comprehensive Income]Consolidated Statements of Income(Millions of yen)
FY2015FY2016(From April 1, 2015
(From April 1, 2016
to December 31, 2015) to December 31, 2016)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Reversal of allowance for doubtful accounts
Other
Total non-operating income
Non-operating expenses
Interest expenses
Share of loss of entities accounted for using equity method
Foreign exchange losses
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Gain on sales of investments in capitalof subsidiaries and associates
State subsidy
Other
Total extraordinary income
Extraordinary loss
Loss on sales of noncurrent asssets
Loss on retirement of noncurrent assets
Impairment loss
Loss on sales of investment securities
Loss on step acquisitions
Provision of allowance for doubtful accounts
Loss on reduction of non-current assets
Other
Total extraordinary losses
Income before income taxes
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interests
Net income attributable to owners of parent-8-274,061
187,281
86,77968,34818,431

270,187
180,597
89,58963,441
26,148

588
881
455
1,032
2,958

366
925
22
940
2,254

3,225
95
2,239
1,945
7,505
13,884

2,775
－
209
1,717
4,702
23,700

272
1,601

68
－

50
130
2,054

799
9
877

23
199
51
289
2,238
816
47
234
3,900
12,038
5,863(7,830)(1,967)
14,00637
13,968

480
265
0
0
－
－
784
485
2,017
22,560
7,588
651
8,240
14,320249
14,071

Consolidated Statements of Comprehensive Income(Millions of yen)
FY2015FY2016(From April 1, 2015
(From April 1, 2016
to December 31, 2015) to December 31, 2016)

Net income
Other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Share of other comprehensive income ofentities accounted for using equity method
Total other comprehensive income
Comprehensive income
Comprehensive income
attributable to owners of parent
Comprehensive income
attributable to non-controlling interests-9-14,006

14,3201,648(53)(9,982)
79
(1)

2,734
(220)
(20,781)112－(8,309)
5,696
5,903

(18,154)(3,833)(3,083)

(206)

(750)

(3) Notes Regarding Consolidated Financial Statement(Notes regarding going concern)
N/A(Notes regarding significant changes in the amount of shareholders' equity)
The Company repurchased 3,889,200 shares of its own common stocks in accordance with the provisions of Article
156 of the Companies Act, as applied pursuant to the provisions of Paragraph 3, Article 165 of the Companies Act,after authorization at the Board of Directors’ Meeting held on June 28, 2016.
Due to the repurchase, treasury shares increased by 4,806 million yen during the three-month period ended
December 31, 2016 to 6,282 million yen as of the end of that period.

(Segment Information)Ⅰ

FY2015 (From April 1, 2015 to December 31, 2015)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

PharmaPackaging

Total

Other
(Note.1)

Total

Consolidated
Statements ofIncome(Note.3)

Adjustment(Note.2)

Net sales(1)Sales to third parties

202,837

46,267

24,932

274,03724

274,061-

274,061(2)Inter-segment sales
and transfers

1,327

6,425

685

8,438

28

8,466

(8,466)-

Total

204,164

52,692

25,618282,47552

282,528(8,466)

274,061

Segment profit

21,5558,168(1,063)

28,66050

28,711(10,280)

18,431(Notes)1.
2.

3.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (10,280) million yen includes deduction of intercompany profits on inventoriesof (201) million yen and corporate cost of (10,078) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

.
2.

Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment

Significant Change in Amount of Goodwill
In Medical-Related Business, we have consolidated Infraredx, Inc. after acquisition of its stocks. Due to this,Goodwill increased by 6,478 million yen from the end of the previous fiscal year.

- 10 -

Ⅱ
1.

FY2016 (From April 1, 2016 to December 31, 2016)
Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

PharmaPackaging

Total

Other
(Note.1)

Total

Consolidated
Statements ofIncome(Note.3)

Adjustment(Note.2)

Net sales(1)Sales to third parties

195,656

52,902

21,605

270,16422

270,187-

270,187(2)Inter-segment sales
and transfers

1,202

7,296

0

8,499

483

8,983

(8,983)-

Total

196,859

60,19821,605

278,664505

279,170(8,983)

270,187

Segment profit

24,19812,732(760)

36,16965

36,235(10,086)

26,148(Notes)1.
2.

3.

“Other” is the business segment which is not included in the segment and consists of real estate income and sales
by headquarter.
Adjustment for the segment profit of (10,086) million yen includes realization of intercompany profits oninventories of 1,513 million yen and corporate cost of (11,599) million yen. Corporate cost consists primarily ofgeneral and administrative expenses and research and development cost which do not belong to the reporting
segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Changes in Reportable Segments
The Company has changed a name of reportable segment from the beginning of the first quarter in FY2016. Former
Glass-Related Business is newly named PharmaPackaging Business.
The change is only in name and has no effects on the business classification or the figures from the third quarter in theprevious fiscal year. The Segment Information for FY2015 (From April 1, 2015 to December 31, 2015) reflects this change
and the current segment name is used.
3. Information on Impairment Loss on Fixed Assets and on Goodwill by Reportable Segment
N/A- 11 -